Trial · NCT06598969
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT06598969, Phase 2, Not yet recruiting, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. Trials, record NCT06598969. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06598969
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
- NCT number
- NCT06598969
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 58 participants, estimated
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Conditions
- Myelodysplastic Syndromes, Myeloid Leukemia, Acute
- Interventions
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From the start of therapy to 2 years after post-transplant | Time from the start of treatment to the date of death, disease relapse/progression, or date of last follow-up. |
| Secondary | Overall survival | From the start of therapy to 2 years after post-transplant | Quantification of time of patients who are still alive |
| Secondary | Cumulative incidence of recurrence/progression | From the start of therapy to 2 years after post-transplant | The event is relapse/progression either extramedullary or at bone marrow |
| Secondary | Complete remission rate | From the day of infusion to the day 30 post-transplant | The event is whether or not the patient has a documented complete remission |
| Secondary | Non-relapse mortality | From the start of therapy until 2 years after post-transplant | Number of deaths from causes other than relapse or progression |
| Secondary | Measurable residual disease | At 30, 90, 180 days and 1 year, 1.5 year and 2 years post-transplant | Measurable residual disease monitoring assessed by multiparameter flow cytometry |
| Secondary | Incidence of infection | 2 years after post-transplant | Describe the infections. |
| Secondary | Adverse Events | 2 years after post-transplant | Describe the adverse event |
| Secondary | Acute graft-versus-host disease grades 2-4 and 3-4 | 100 days post-transplant | This point is classified according to the consensus MAGIC classification |
| Secondary | Chronic graft-versus-host disease | 2 years after post-transplant | Describe the chronic graft-versus-host disease according to the National Institutes of Health Stroke Scale consensus staging. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06598969
GET https://conductscience.org/api/trials/v1/NCT06598969/registered